Clinical Trial Update: Sorafenib and RAD001 Renal Cell Carcinoma [Phase 1]

View source ↗

Summary

This entry reports a completed Phase 1 trial evaluating the combination of sorafenib and RAD001 (everolimus) in renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Afinitor (everolimus)
• Nexavar (Sorafenib)

Snippet

Sponsor: University of California, San Francisco | Conditions: Renal Cell Carcinoma | Phase 1 | Status: COMPLETED